Krishna Institute of Medical Sciences (KIMS) reported a 47% decline in Q1 FY27 net profit to ₹41.5 crore, even as revenue rose 35% to ₹1,179.5 crore. The results were hit by margin compression, which fell to 18.9% from 22.1% a year ago, reflecting the cost of aggressive bed expansion and new facility operations.
Krishna Institute of Medical Sciences (KIMS) faced a challenging first quarter for the financial year 2027, as net profit fell by 47.2% to ₹41.5 crore. This sharp decline in bottom-line performance arrived despite a strong 35.3% growth in revenue from operations, which climbed to ₹1,179.5 crore. The company, which is aggressively expanding its footprint, now manages a total capacity of 7,459 beds following the opening of a new hospital facility in Palakkad, Kerala.
Impact of Margin Pressure on Earnings
While the company saw a 16% increase in operating profit, or EBITDA, to ₹223.4 crore, the operating margin narrowed significantly to 18.9% from 22.1% in the same period last year. For investors, this margin compression is a key factor, as it indicates that higher costs associated with scaling the hospital network and managing new facilities are currently outpacing the revenue gains. Management noted that newer hospitals are performing well and conducting complex medical procedures, such as lung transplants, yet the initial costs of setting up and ramping up these units continue to weigh on overall profitability.
Capital Allocation and Fundraising Plans
The company is continuing its capital-intensive expansion strategy. KIMS previously raised ₹1,500 crore through a Qualified Institutional Placement in FY26, with a portion of these funds currently held in mutual funds and monitoring accounts to support future growth. In a further move to strengthen its balance sheet and fund expansion, the board has approved a plan to raise up to ₹600 crore through the issue of 77 lakh convertible warrants to promoters and related entities. These warrants are priced at ₹779 per share and provide a window of 18 months for conversion into equity, pending necessary regulatory approvals.
Additionally, the company has expanded its portfolio by entering into a hospital operations and management agreement with another healthcare entity. This transaction has been structured as a business combination, reflecting the company’s intent to grow through both greenfield expansion and operational control of existing facilities.
Looking ahead, investors may monitor whether the newly added capacity in regions like Kerala begins to translate into improved profit margins. The primary tracker for the coming quarters will be the company’s ability to stabilize costs in its newer hospitals and improve its operating margins back toward historical levels, alongside the progress of its ongoing integration of newly acquired operations.